Phase 3 Alopecia Areata Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with alopecia areata (a condition causing patchy hair loss), and your current episode has been ongoing for at least 6 months but no longer than 10 years
- You are between 12 and 17 years old
- You have lost at least 50% of the hair on your scalp, as measured by a standard hair loss scoring tool
- You are willing and able to attend all required study visits and follow the study's guidelines
Who may not be able to join:
- You have an active scalp condition such as inflammation, psoriasis, or a flaky/itchy scalp that needs treatment, significant scalp injury, or untreated abnormal skin growths on the scalp
- You have taken medications in the past 28 days, or plan to take medications during the study, that could affect hair regrowth or your immune system
- You are female and are currently pregnant, breastfeeding, or planning to become pregnant during the study or within 30 days after your last dose of the study medication
- You have a significant physical health condition, mental health condition, or personal/social situation that the study doctor believes could make participation risky or affect the study's results (confirm with trial site)
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 9122 66455645
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of subjects achieving an absolute Severity of Alopecia Tool (SALT) score ≤20; Safety and tolerability of deuruxolitinib will be assessed by evaluating adverse events, vital signs, electrocardiograms, and clinical laboratory results, as well as physical examinations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.